Ophthalmics
The primary focus of our ophthalmology portfolio is refractive errors, which affects over 4 billion people worldwide.
Our leading drug candidate, NVK-002, targets pediatric myopia, a childhood eye condition of epidemic proportions.
Pharmacologic Interventions to Treat Refractive Errors
Refractive errors occur when the shape of the eye prevents light from focusing correctly on the retina, making it difficult to see clearly. They represent the most common type of vision problem and affect more than 150 million Americans. The leading types of refractive errors include myopia, hyperopia, astigmatism, and presbyopia.
For years, glasses, contacts, and surgical procedures were the primary means of refractive error correction. Even with recent innovation in these treatment options, there remains a significant unmet need in treating refractive errors using pharmacologic interventions. Our focus is on developing novel ophthalmic pharmaceutical treatments that have the potential to transform the way these conditions are managed.
NEVAKAR’S PIPELINE FOCUSED ON TREATING REFRACTIVE ERRORS
Pediatric Myopia – Pediatric myopia is a childhood eye condition of epidemic proportions. This common diagnosis makes it difficult for children to see distant objects and can complicate daily activities. It is now understood that uncorrected myopia can lead to severe complications later on in life. Learn more about our novel treatment approach for progressive myopia in children.
Ophthalmic Products
| Product CandidatesTherapeutic Area | Research | Preclinical | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|
| NVK-002Atropine for Children with Myopia (US & Europe) | Research | Preclinical | Phase I | Phase II | Phase III |
| NVK-002Atropine for Children with Myopia (Asia) | Research | Preclinical | Phase I | Phase II | Phase III |
| NVK-029Refractive errors I | Research | Preclinical | Phase I | Phase II | Phase III |
| NVK-031Refractive errors II | Research | Preclinical | Phase I | Phase II | Phase III |